+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-01-14Number of Pages: 117

Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020


Human papillomavirus (HPV) and cytomegalovirus (CMV) are viral pathogens affecting individuals of all ages. HPV causes serious sexually transmitted diseases (STDs), while CMV is an opportunistic pathogen affecting immunocompromised individuals such as HIV patients. The global market for HPV and CMV therapeutics is expected to experience a surge due to various macro and micro economic factors.     

More than 100 strains of HPV have been identified till date, of which certain types are known to cause warts or papillomas that progress to benign or malignant cancers. HPV infections are common in adolescents and young adults with highest prevalence in adolescent females. According to CDC, in 2012, an estimated 20 million persons were infected that year in the U.S., and an estimated 6.2 million new HPV infections were expected to occur annually. The human papillomavirus therapeutics market includes immunomodulators, keratolytic agents, anti-neoplastic agents and sinecatechins. Immunomodulators account for the largest share of the global HPV therapeutics market, while the sinecatechins segment is expected to be the fastest growing market segment. Genital warts is the leading application segment in HPV therapeutics market in terms of revenue generation, due to higher number of HPV strains leading to genital warts which are easily transmitted through sexual contact. Dry therapeutic pipeline and serious threat from substitutes such as cryotherapy and laser therapy have made the market less attractive. Asia Pacific and South America are observed to be the most attractive markets due to developing healthcare infrastructure, high disposable income, and cultural shifts and tourism augmenting the prevalence of STDs. The global HPV therapeutics market was valued at USD 1,402.3 million in 2012 and is expected to reach USD 2,346.5 million by 2020, growing at a CAGR of 7.7% from 2014 to 2020. 

Cytomegalovirus infections are usually asymptomatic and do not need therapeutic treatment for immunocompetent patients. However, the virus causes inflammation of the eye called as retinitis in patients with weak immune system. Thus, prevalence of symptomatic CMV infections is common in HIV and transplant patients. Ganciclovir and valganciclovir are the two first line drugs prescribed for treating CMV infections. These account for over 85% revenue share of the global CMV therapeutics market. High seroprevalence of up to 95% in low and middle income countries has posed CMV infection threat to a large population. Furthermore, high rate of resistance for ganciclovir and valganciclovir in HIV patients is also a major concern in these countries. Anticipating launch of brincidofovir in 2016 and letermovir in 2018, the CMV therapeutics market is expected to grow rapidly in the near future. The global CMV therapeutics market was valued at USD 870.1 million in 2012 and is expected to reach USD 922.8 million by 2020, growing at a CAGR of 1.49 % from 2014 to 2020.

Valeant Pharmaceuticals dominates the global HPV therapeutics market with more than 70% market share while Roche AG leads the CMV therapeutics market with over 85% share. Other key players in the HPV and CMV therapeutics market include Fougera Pharmaceuticals, Perrigo Company plc, Clinigen Group plc and Fresenius Kabi USA.

hpv-cmv-therapeutics-market

 

 

Chapter 1 Introduction

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

1.4 Assumptions

1.5 List of Abbreviations

 

Chapter 2 Executive Summary

2.1 Market Snapshot: Global HPV Therapeutics Market

2.2 Market Snapshot: Global CMV Therapeutics Market

2.3 Global HPV and CMV Therapeutics Market  Revenue, 2012 – 2020 (USD Million)

 

Chapter 3 Global HPV and CMV Therapeutics Market Overview

3.1 Market Definition and Overview

3.2 Market Dynamics

      3.2.1 Human Papillomavirus (HPV) Therapeutics Market

              3.2.1.1 Drivers

                         3.2.1.1.1 Increasing prevalence of HPV infections in developing and underdeveloped economies is aiding the market growth

                         3.2.1.1.2 Global Age-specific incidence of cervical cancer

                         3.2.1.1.3 Severe side-effects of HPV vaccines are restraining the market growth and creating opportunity for therapeutics market

              3.2.1.2 Restraints

                         3.2.1.2.1 Increasing demand for minimally invasive surgical procedures in genital warts treatment

                         3.2.1.2.2 Lack of awareness in developing areas is declining the diagnostic rates

                                      3.2.1.2.2.1 Annual number of new cases (in thousands) of cervical cancer by age group in developed and developing regions (estimations for 2012)

              3.2.1.3 Opportunities

                         3.2.1.3.1 Opportunity for biologics and drugs with low toxicity and short treatment regime against HPV infections

                         3.2.1.3.2 Health issues raised against approved vaccines have provided wide range of opportunities for effective and safe vaccines and therapeutics

      3.2.2 Cytomegalovirus Therapeutics Market

              3.2.2.1 Drivers

                         3.2.2.1.1 High seroprevalence adding to patient pool for CMV therapeutics market

                         3.2.2.1.2 High global demand for low-cost generic drugs, especially in low- and middle-income countries in South Latin America and Asia Pacific

              3.2.2.2 Restraints

                         3.2.2.2.1 Decreasing CMV prevalence due to highly actively antiretroviral therapy (HAART) and decreasing transplant procedures

              3.2.2.3 Opportunities

                         3.2.2.3.1 Less competition in pediatric CMV therapeutics and increasing demand for CMV vaccine

3.3 Value Chain Analysis

3.4 HPV Vaccines : Current Global Scenario

3.5 HPV Drug Treatment Regime Analysis: Length of HPV Drug treatment (No. of days)

3.6 HPV Surgery Treatment: Type of Surgery and Average Cost (USD)

3.7 Pricing Analysis

      3.7.1 Pricing Analysis: HPV Therapeutics Market

      3.7.2 Pricing Analysis: CMV Therapeutics Market

      3.7.3 HPV Treatment Cost Analysis

      3.7.4 CMV Treatment Cost Analysis

3.8 Porter’s Five Forces Analysis: Global HPV & CMV Therapeutics Market

      3.8.1 Bargaining Power of Suppliers

      3.8.2 Bargaining Power of Buyers

      3.8.3 Threat of Substitutes

      3.8.4 Threat of New Entrants

      3.8.5 Competitive Rivalry

3.9 Market Attractiveness Analysis, by Geography, 2013

      3.9.1 HPV Therapeutics Market Attractiveness Analysis, Geography, 2013

      3.9.2 CMV Therapeutics Market Attractiveness Analysis, by Geography, 2013

3.10 Market Share Analysis, by Key Players, 2013 (Value %)

      3.10.1 HPV Therapeutics Market Share Analysis, by Key Players, 2013 (Value %)

      3.10.2 CMV Therapeutics Market Share Analysis, by Key Players, 2013 (Value %)

 

Chapter 4 Global  HPV Therapeutics Market

4.1 Overview

4.2 HPV Therapeutics Market, by Drug Class

      4.2.1 Overview

              4.2.1.1 Global HPV Therapeutics Market Revenue, by Major Drug Classes, 2012 - 2020 (USD Million)

      4.2.2 Immunomodulators

              4.2.2.1 Global Immunomodulators Market Revenue, 2012 – 2020 (USD Million)

      4.2.3 Keratolytic Agents

              4.2.3.1 Global Keratolytic Agents Market Revenue, 2012 – 2020 (USD Million)

      4.2.4 Anti-neoplastic Agents

              4.2.4.1 Global Anti-neoplastic Agents Market Revenue, 2012 – 2020 (USD Million)

      4.2.5 Sinecatechins

              4.2.5.1 Global Sinecatechins Market Revenue, 2012 – 2020 (USD Million)

4.3 HPV Therapeutics Market, by Application

      4.3.1 Overview

              4.3.1.1 Global HPV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)

      4.3.2 Genital Warts

              4.3.2.1 Global Genital Warts HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      4.3.3 Genital Cancer

              4.3.3.1 Global Genital Cancer HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      4.3.4 Epidermodysplasia Verruciformis

              4.3.4.1 Global Epidermodysplasia Verruciformis HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      4.3.5 Oral Papillomas

              4.3.5.1 Global Oral Papillomas HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      4.3.6 Others (Oropharyngeal cancer, laryngeal papillomatosis and others)

              4.3.6.1 Global Other (Oropharyngeal Cancer, Laryngeal Papillomatosis and Others) HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

4.4 HPV Therapeutics Market, Pipeline Analysis

      4.4.1 HPV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates

      4.4.2 HPV Therapeutics: Late Stage (Phase III) Drug Candidates

 

Chapter 5 Global Cytomegalovirus Therapeutics Market

5.1 Introduction

      5.1.1 Global CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

5.2 CMV Therapeutics Market, by Major Antiviral Drugs

      5.2.1 Overview

              5.2.1.1 Global CMV Therapeutics Market Revenue, by Drugs, 2012 - 2020 (USD Million)

      5.2.2 Ganciclovir/Valganciclovir

              5.2.2.1 Global Ganciclovir/Valganciclovir Market Revenue, 2012 - 2020 (USD Million)

      5.2.3 Foscarnet

              5.2.3.1 Global Foscarnet Market Revenue, 2012 - 2020 (USD Million)

      5.2.4 Cidofovir

              5.2.4.1 Global Cidofovir Market Revenue, 2012 - 2020 (USD Million)

5.3 CMV Therapeutics Market, by Applications

      5.3.1 Overview

              5.3.1.1 Global CMV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)

      5.3.2 CMV Retinitis

              5.3.2.1 Global CMV Retinitis Therapeutics Market Revenue,2012 - 2020 (USD Million)

      5.3.3 Pneumonia

              5.3.3.1 Global CMV Pneumonia Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      5.3.4 Gastrointestinal ulcers

              5.3.4.1 Global CMV Gastrointestinal Ulcers Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      5.3.5 Encephalitis

              5.3.5.1 Global CMV Encephalitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      5.3.6 Others (Mouth ulcers, pharyngitis)

              5.3.6.1 Global Other (Mouth ulcers, Pharyngitis)CMV Therapeutics Market Revenue,2012 - 2020 (USD Million)

5.4 CMV Therapeutics Market, Pipeline Analysis

      5.4.1 CMV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates

      5.4.2 CMV Therapeutics: Late Stage (Phase III) Drug Candidates

              5.4.2.1 Introduction

                         5.4.2.1.1 MK8228/ letermovir/AIC246

                                      5.4.2.1.1.1 Global Letermovir Market Revenue, 2018 - 2020 (USD Million)

                         5.4.2.1.2 Brincidofovir/CMX001

                                      5.4.2.1.2.1 Global Brincidofovir Market Revenue, 2016 - 2020 (USD Million)

 

Chapter 6 Global HPV and CMV Therapeutics Market, by Geography

6.1 Overview

      6.1.1 Global HPV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

              6.1.1.1 Global CMV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

6.2 North America

      6.2.1 North America HPV Therapeutics Market

              6.2.1.1 North America HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      6.2.2 North America CMV Therapeutics Market

              6.2.2.1 North America CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

6.3 Europe

      6.3.1 Europe HPV Therapeutics Market

              6.3.1.1 Europe HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      6.3.2 Europe CMV Therapeutics Market

              6.3.2.1 Europe CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

6.4 Asia Pacific

      6.4.1 Asia Pacific HPV Therapeutics Market

              6.4.1.1 Asia Pacific HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      6.4.2 Asia Pacific CMV Therapeutics Market

              6.4.2.1 Asia Pacific CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

6.5 South America

      6.5.1 South America HPV Therapeutics Market

              6.5.1.1 South America HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      6.5.2 South America CMV Therapeutics Market

              6.5.2.1 South America CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

6.6 Rest of the World

      6.6.1 Rest of the World HPV Therapeutics Market

              6.6.1.1 Rest of the World HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      6.6.2 Rest of the World CMV Therapeutics Market

              6.6.2.1 Rest of the World CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

 

Chapter 7 Recommendations

      7.1.1 Market avails wide scope for new molecules as most of the first line drugs have been off patented

      7.1.2 Building stronger market hold in Africa

 

Chapter 8 Company Profiles

8.1 AbbVie, Inc.

      8.1.1 Company Overview

      8.1.2 Financial Overview

      8.1.3 Product Portfolio

      8.1.4 Business Strategies

              8.1.4.1 Strategic Collaborations and Agreements

      8.1.5 Mergers and Acquisitions

      8.1.6 Recent Developments

8.2 Actavis plc

      8.2.1 Company Overview

      8.2.2 Financial Overview

      8.2.3 Product Portfolio

      8.2.4 Business Strategies

              8.2.4.1 Mergers and acquisitions

              8.2.4.2 Extensive R&D practices

              8.2.4.3 Strategic collaborations

      8.2.5 Recent Developments

8.3 Clinigen Group plc

      8.3.1 Company Overview

      8.3.2 Financial Overview

      8.3.3 Product Portfolio

      8.3.4 Business Strategies

              8.3.4.1 Mergers and Acquisitions

      8.3.5 Recent Developments

8.4 Merck & Co., Inc.

      8.4.1 Company Overview

      8.4.2 Financial Overview

      8.4.3 Product Portfolio

      8.4.4 Business Strategies

              8.4.4.1 Mergers and acquisitions

              8.4.4.2 Strategic collaborations

              8.4.4.3 Expansion in emerging markets

      8.4.5 Recent Developments

8.5 Perrigo Company plc

      8.5.1 Company Overview

      8.5.2 Financial Overview

      8.5.3 Product Portfolio

      8.5.4 Business Strategies

      8.5.5 Mergers and Acquisitions

      8.5.6 Recent Developments

8.6 Roche Holdings AG

      8.6.1 Company Overview

      8.6.2 Financial Overview

      8.6.3 Product Portfolio

      8.6.4 Business Strategies

              8.6.4.1 Consistent product launches

              8.6.4.2 Mergers and Acquisitions

      8.6.5 Recent Developments

8.7 Valeant Pharmaceuticals International, Inc.

      8.7.1 Company Overview

      8.7.2 Financial Overview

      8.7.3 Product Portfolio

      8.7.4 Business Strategies

              8.7.4.1 Mergers and acquisitions

      8.7.5 Recent Developments

List of Figures

 

FIG. 1 HPV Therapeutics: Market Segmentation

FIG. 2 CMV Therapeutics: Market Segmentation

FIG. 3 Global HPV and CMV Therapeutics Market  Revenue, 2012 – 2020 (USD Million)

FIG. 4 Global Age-specific incidence of cervical cancer

FIG. 5 Annual number of new cases (in thousands) of cervical cancer by age group in developed and developing regions and five continents (estimations for 2012)

FIG. 6 Heat Map Analysis: Immunization Array of Currently Marketed Vaccines by Major Countries

FIG. 7 Global Human Immunodeficiency Virus (HIV) Prevalence, 1990 - 2008

FIG. 8 U.S. Transplant Procedures,  2000 - 2013

FIG. 9 Global HPV and CMV Therapeutics Market, Value Chain Analysis

FIG. 10 Porter’s Five Forces Analysis for the Global HPV & CMV Therapeutics Market

FIG. 11 HPV Therapeutics Market Attractiveness Analysis: by Geography, 2013

FIG. 12 CMV Therapeutics Market Attractiveness Analysis, by Geography, 2013

FIG. 13 HPV Therapeutics Market Share Analysis: by Key Players, 2013 (Value %)

FIG. 14 CMV Therapeutics Market Attractiveness Analysis: by Key Players, 2013 (Value %)

FIG. 15 Global Immunomodulators Market Revenue, 2012 – 2020 (USD Million)

FIG. 16 Global Keratolytic Agents Market Revenue, 2012 – 2020 (USD Million)

FIG. 17 Global Anti-neoplastic Agents Market Revenue, 2012 – 2020 (USD Million)

FIG. 18 Global Sinecatechins Market Revenue, 2012 – 2020 (USD Million)

FIG. 19 Global Genital Warts HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 20 Global Genital Cancer HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 21 Global Epidermodysplasia Verruciformis HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 22 Global Oral Papillomas HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 23 Global Other (Oropharyngeal Cancer, Laryngeal Papillomatosis and Others) HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 24 Global Ganciclovir/Valganciclovir Market Revenue, 2012 - 2020 (USD Million)

FIG. 25 Global Foscarnet Market Revenue, 2012 - 2020 (USD Million)

FIG. 26 Global Cidofovir Market Revenue, 2012 - 2020 (USD Million)

FIG. 27 Global CMV Retinitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 28 Global CMV Pneumonia Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 29 Global CMV Gastrointestinal Ulcers Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 30 Global CMV Encephalitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 31 Global Other (Mouth ulcers, Pharyngitis) CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 32 Global Letermovir Market Revenue, 2018 - 2020 (USD Million)

FIG. 33 Global Brincidofovir Market Revenue, 2016 - 2020 (USD Million)

FIG. 34 North America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 35 North America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 36 Europe HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 37 Europe CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 38 Asia Pacific HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 39 Asia Pacific CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 40 South America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 41 South America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 42 Rest of the World HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 43 Rest of the World CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 44 Tuberculosis Cases in Africa, 1996 – 2010 (‘000)

FIG. 45 AbbVie, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 46 Actavis Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 47 Clinigen Group plc: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 48 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 49 Perrigo Company plc: Annual Revenue: 2011 – 2013 (USD Million)

FIG. 50 Roche Holdings AG: Annual Revenue: 2011 – 2013 (USD Million)

FIG. 51 Valeant Pharmaceuticals International, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables

 

TABLE 1 Market Snapshot: Global HPV Therapeutics Market

TABLE 2 Market Snapshot: Global CMV Therapeutics Market

TABLE 3 HPV Vaccines Sales Track

TABLE 4 Pricing Analysis: HPV Therapeutics Market

TABLE 5 Pricing Analysis: CMV Therapeutics Market

TABLE 6 HPV Strains and Diseases

TABLE 7 Global HPV Therapeutics Market Revenue, by Major Drug Classes, 2012 - 2020 (USD Million)

TABLE 8 Global HPV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)

TABLE 9 HPV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates

TABLE 10 Global CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

TABLE 11 Global CMV Therapeutics Market Revenue, by Drugs, 2012 - 2020 (USD Million)

TABLE 12 Global CMV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)

TABLE 13 CMV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates

TABLE 14 Global HPV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

TABLE 15 Global CMV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

 

Human papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market report studies current as well as future prospects of the market on a global scale. The global market for HPV therapeutics is segmented by drug class and applications. Various drug classes applied against HPV infections are immunomodulators, keratolytic agents, anti-neoplastic agents, and sinecatechins. The HPV therapeutics market is studied by application segments which include genital warts, genital cancers, epidermodysplasia verriformis, oral papillomas, and others (oropharyngeal cancer, laryngeal papillomatosis and others). The global HPV therapeutics market has been extensively analyzed on the basis of the effectiveness and sales revenue of major drug classes as well as geographic prevalence of various HPV infections. 

 

The global CMV therapeutics market is segmented by drugs and applications. The major drugs prescribed for the treatment of CMV infections are ganciclovir, valganciclovir, foscarnet, and cidofovir. The CMV therapeutics treatment is applied against various CMV infections causing retinitis, pneumonia, gastrointestinal ulcers, encephalitis and others (mouth ulcers, pharyngitis and others). 

 

Geographically, the HPV and CMV therapeutics market has been categorized into five regions namely, North America, Europe, South America, Asia Pacific, and Rest of the World (ROW). The market size and forecast in terms of USD million for each of these segments has been provided for the period 2012 to 2020, considering 2012 and 2013 as base years. The HPV and CMV therapeutics market report also provides compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020. 

 

The report also provides pipeline analysis for HPV and CMV therapeutics market, which includes sales forecast for drug candidates currently under phase III clinical trials, and also mentions other candidates in phase I and phase II trials. The research study explains the competitive scenario in the HPV and CMV therapeutics market through Porter’s Five Forces Analysis. A detailed analysis of various macro as well as micro economic factors driving as well as restraining the growth of this market, in addition to future opportunities, is provided in the market overview section of the report. The report also provides market attractiveness analysis and value chain analysis of the global HPV and CMV therapeutics market. Market share analysis for both HPV and CMV therapeutics market has been included. Furthermore, pricing analysis of therapeutic drugs and costs associated with treatment is also studied in the global HPV and CMV therapeutics market report.  

 

A list of recommendations has been provided to help players establish a strong presence in the market and increase their share. The report also profiles major players in the HPV and CMV therapeutics market on the basis of various attributes such as company overview, financial overview, product portfolio, business strategies and recent developments. Mergers, acquisitions, regulatory approvals and other events have been explained in the company profiles section. Key players profiled in the report include AbbVie, Inc., Actavis plc, Clinigen Group plc, Merck & Co., Inc., Perrigo Company plc, Roche Holdings AG and Valeant Pharmaceuticals International, Inc.

 

The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed the real time market scenario. This primary research represented the bulk of our research efforts, which was further supplemented by extensive secondary research. A bottom-up approach was adopted to arrive at global market shares for 2012 and 2013; while an impact based analysis model was adopted to forecast revenue for each market segment. A review of key players’ product literature, annual reports, and press releases supported the market forecast analysis. The 117 pages global HPV and CMV therapeutics market report describes various market dynamics in 51 figures and charts and 16 tables.


 
 
Back To Top